Extract
In their correspondence, Chang Liu and co-workers indicate that we failed to consider homing or the paracrine properties of mesenchymal stromal cells (MSCs) in the regulation of miR-193b-5p and occludin. The authors also state that we failed to show the expression levels of inflammatory factors, and the downstream signalling involved. The concerns raised reflect a misunderstanding of the aim of our study and the body of work that preceded it [1]. The original animal experiment was first published in the American Journal of Respiratory and Critical Care Medicine in 2010 [2].
Abstract
The therapeutic effect of mesenchymal stromal cells (MSCs) is in part due to regulation of host-derived epigenetic modulators – microRNAs – which in turn regulate the transcriptional response to inflammation and injury in a pre-clinical model of ALI https://bit.ly/3jMzCw2
Footnotes
Conflict of interest: C.C. dos Santos and C.M. Vaswani report (founding members, equity stake) of NorthMiRs, outside the submitted work. D.J. Stewart reports other (founding member, equity stake) from Northern Therapeutics, outside the submitted work. The remaining authors have no potential conflicts of interest to disclose.
- Received April 28, 2022.
- Accepted December 29, 2022.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org